Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
250 participants
OBSERVATIONAL
2022-11-11
2023-04-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* To identify new relevant biomarkers in patients who will carry a pregnancy to term
* To better specify or identify new infertility risk factors
* To identify new relevant biomarkers in patients with reduced ovarian reserve
Four consultations are planned with biological et clinical collection.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* a consultation 2 summarizing the examinations and delivery of prescriptions
* a blood sample: basal hormonal assessment with AMH (Anti-Mullerian Hormone),
* a urine sample to look for an infection with Chlamydia Trachomatis, which is one of the bacteria responsible for gynecological infections compromising ART.
* an HPV (Human Papillomavirus) test on vaginal swab
* a consultation 3 corresponding to the start of a treatment cycle for IVF with oocyte retrieval at the end of this treatment cycle.
* A consultation lasting 4 to 4-6 weeks to take stock of the success or failure of the ART.
* A pregnancy follow-up consultation if successful, for a pelvic ultrasound, then monthly pregnancy follow-up (one consultation per month).
* As part of the usual ART monitoring, clinical and paraclinical data are collected using the MEDIFIRST software.
* During the inclusion visit, questionnaire =\> will be completed over an additional time to the consultation if inclusion is desired, inclusion time provided by one of the doctors participating in the study.
For the FERTITHEQUE, will be collected:
* clinical characteristics collected at each consultation as part of the usual follow-up.
* biological characteristics measured as part of the usual follow-up.
* During consultation 2, during a blood test carried out as part of your usual care, additional tubes will be taken (4 to 5 tubes of 10mL) to carry out the banking of DNA (support of genetic information), plasma (plasma library), serum (serotheque).
* During consultation 2, a swab will also be taken from the vaginal microbiota.
* During consultation 3, a conservation of the follicular fluid (puncture fluid) will be carried out.
* During consultation 4, a plasma library will be performed again, whether there is pregnancy or not, as well as a new swab sample for the vaginal microbiota.
Then, as described above, patients are after inclusion as part of the usual IVF follow-up reviewed at 1 month for oocyte retrieval then at 2 months for the follow-up visit allowing observation of success or failure of the treatment cycle.
* If pregnancy is achieved, patients are seen monthly as part of their usual follow-up until delivery.
* If a pregnancy is not achieved, follow-up stops.
* Whether or not a pregnancy is obtained, during the visit at 2 months (V4), a plasma library and a vaginal microbiota are again performed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CASE
Patients who did not carry a pregnancy to term
Biocollection
For the FERTITHEQUE, will be collected:
* Clinical characteristics
* Biological characteristics measured as part of the usual follow-up
* consultation n°2 : DNA
* consultation n°2 : plasma
* consultation n°2 : serum
* consultation n°2 : vaginal microbiota
* consultation n°3 : follicular fluid (puncture fluid)
* consultation n°4 : plasma
* consultation n°4 : vaginal microbiota.
CONTROL
patients who carried a pregnancy to term
Biocollection
For the FERTITHEQUE, will be collected:
* Clinical characteristics
* Biological characteristics measured as part of the usual follow-up
* consultation n°2 : DNA
* consultation n°2 : plasma
* consultation n°2 : serum
* consultation n°2 : vaginal microbiota
* consultation n°3 : follicular fluid (puncture fluid)
* consultation n°4 : plasma
* consultation n°4 : vaginal microbiota.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Biocollection
For the FERTITHEQUE, will be collected:
* Clinical characteristics
* Biological characteristics measured as part of the usual follow-up
* consultation n°2 : DNA
* consultation n°2 : plasma
* consultation n°2 : serum
* consultation n°2 : vaginal microbiota
* consultation n°3 : follicular fluid (puncture fluid)
* consultation n°4 : plasma
* consultation n°4 : vaginal microbiota.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged 18 to 43
* Infertility for at least 12 months
* Oriented in IVF
* Infertility of unexplained origin or presenting a low ovarian reserve before the age of 35 (AMH\<1.1ng and/or CFA\<7).
Exclusion Criteria
* Patients under guardianship, curatorship (legal protection)
* Refusal to participate
* Patient unable to consent
18 Years
43 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Brest
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHRU de Brest
Brest, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
29BRC21.0053
Identifier Type: -
Identifier Source: org_study_id